LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Momelotinib | 3.33 | uM | LJP5 | 72 | hr | 868 | 2047 | 3410 | 0.6007 | 0.5445 |
MDA-MB-231 | Momelotinib | 10 | uM | LJP5 | 72 | hr | 868 | 939 | 3410 | 0.2749 | 0.0384 |
MDA-MB-231 | Fedratinib | 0.04 | uM | LJP5 | 72 | hr | 868 | 3697 | 3410 | 1.0836 | 1.0820 |
MDA-MB-231 | Fedratinib | 0.12 | uM | LJP5 | 72 | hr | 868 | 3410 | 3410 | 0.9987 | 0.9970 |
MDA-MB-231 | Fedratinib | 0.37 | uM | LJP5 | 72 | hr | 868 | 3137 | 3410 | 0.9202 | 0.9177 |
MDA-MB-231 | Fedratinib | 1.11 | uM | LJP5 | 72 | hr | 868 | 2260 | 3410 | 0.6627 | 0.6231 |
MDA-MB-231 | Fedratinib | 3.33 | uM | LJP5 | 72 | hr | 868 | 975 | 3410 | 0.2860 | 0.0600 |
MDA-MB-231 | Fedratinib | 10 | uM | LJP5 | 72 | hr | 868 | 618 | 3410 | 0.1819 | -0.1582 |
MDA-MB-231 | Trametinib | 0.04 | uM | LJP5 | 72 | hr | 868 | 1088 | 3410 | 0.3193 | 0.1214 |
MDA-MB-231 | Trametinib | 0.12 | uM | LJP5 | 72 | hr | 868 | 1278 | 3410 | 0.3756 | 0.2170 |
MDA-MB-231 | Trametinib | 0.37 | uM | LJP5 | 72 | hr | 868 | 1199 | 3410 | 0.3524 | 0.1784 |
MDA-MB-231 | Trametinib | 1.11 | uM | LJP5 | 72 | hr | 868 | 1147 | 3410 | 0.3364 | 0.1513 |
MDA-MB-231 | Trametinib | 3.33 | uM | LJP5 | 72 | hr | 868 | 1155 | 3410 | 0.3385 | 0.1548 |
MDA-MB-231 | Trametinib | 10 | uM | LJP5 | 72 | hr | 868 | 1306 | 3410 | 0.3829 | 0.2291 |
MDA-MB-231 | Omipalisib | 0.04 | uM | LJP6 | 72 | hr | 868 | 2095 | 3556 | 0.5898 | 0.5427 |
MDA-MB-231 | Omipalisib | 0.12 | uM | LJP6 | 72 | hr | 868 | 1578 | 3556 | 0.4438 | 0.3404 |
MDA-MB-231 | Omipalisib | 0.37 | uM | LJP6 | 72 | hr | 868 | 1278 | 3556 | 0.3599 | 0.2097 |
MDA-MB-231 | Omipalisib | 1.11 | uM | LJP6 | 72 | hr | 868 | 1044 | 3556 | 0.2931 | 0.0926 |
MDA-MB-231 | Omipalisib | 3.33 | uM | LJP6 | 72 | hr | 868 | 1030 | 3556 | 0.2889 | 0.0843 |
MDA-MB-231 | Omipalisib | 10 | uM | LJP6 | 72 | hr | 868 | 1031 | 3556 | 0.2896 | 0.0849 |
MDA-MB-231 | Buparlisib | 0.04 | uM | LJP5 | 72 | hr | 868 | 3829 | 3410 | 1.1223 | 1.1199 |
MDA-MB-231 | Buparlisib | 0.12 | uM | LJP5 | 72 | hr | 868 | 3425 | 3410 | 1.0048 | 1.0051 |
MDA-MB-231 | Buparlisib | 0.37 | uM | LJP5 | 72 | hr | 868 | 2791 | 3410 | 0.8182 | 0.8062 |
MDA-MB-231 | Buparlisib | 1.11 | uM | LJP5 | 72 | hr | 868 | 1779 | 3410 | 0.5222 | 0.4388 |
MDA-MB-231 | Buparlisib | 3.33 | uM | LJP5 | 72 | hr | 868 | 1135 | 3410 | 0.3333 | 0.1456 |